Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/29/2025 | $18.00 | Buy | Truist |
| 10/16/2024 | $26.00 | Outperform | Oppenheimer |
| 10/3/2024 | $22.00 | Outperform | Wedbush |
| 10/2/2024 | $15.00 | Buy | H.C. Wainwright |
| 9/4/2024 | $16.00 | Outperform | Robert W. Baird |
| 4/3/2024 | $25.00 | Outperform | Leerink Partners |
| 11/17/2023 | $4.50 | Neutral → Buy | Citigroup |
| 10/19/2022 | $12.00 | Buy | Guggenheim |
Truist initiated coverage of Larimar Therapeutics with a rating of Buy and set a new price target of $18.00
Oppenheimer initiated coverage of Larimar Therapeutics with a rating of Outperform and set a new price target of $26.00
Wedbush initiated coverage of Larimar Therapeutics with a rating of Outperform and set a new price target of $22.00
SCHEDULE 13G - Larimar Therapeutics, Inc. (0001374690) (Subject)
SCHEDULE 13G/A - Larimar Therapeutics, Inc. (0001374690) (Subject)
8-K - Larimar Therapeutics, Inc. (0001374690) (Filer)
4 - Larimar Therapeutics, Inc. (0001374690) (Issuer)
4 - Larimar Therapeutics, Inc. (0001374690) (Issuer)
4 - Larimar Therapeutics, Inc. (0001374690) (Issuer)